Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Understanding variation in PK exposure in human dose escalation studies

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: VEDIN, Charlotta (AstraZeneca, Safety and ADME translational sciences, Drug safety and metabolism, Mölndal, Sweden)
  • Co-author(s): Charlotta Vedin: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, Sweden
    Katarina Breitholtz: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, Sweden
    Katherine Fenner: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, United Kingdom
    Constanze Hilgendorf: Safety and ADME translational sciences, Drug safety and metabolism, IMED AstraZeneca, Sweden
    James D Clarke: Oncology DMPK, IMED AstraZeneca, United Kingdom
  • Abstract:

    Backgrounds

    In clinical dose escalation studies the pharmacokinetics of AZ1 exhibited significant variability. The variability was suggested to be caused by limited absorption and/or intestinal metabolism of AZ1.

    Aims

    The permeability and intestinal metabolism of AZ1 were studied in Ussing chamber experiments using fresh human jejunum samples to

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses